Lack of effect of promoter, coding and 3‘ polymorphisms of the β2 -adrenergic receptor (ADRB2 ) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma W. Anderson, E. Bleecker, H. Nelson, J. Corren, A. Emmett, D. Reilly, S. Yancey, H. Ortega (Research Triangle Park, NC, Winston Salem, NC, Denver, CO, Los Angeles, CA, United States Of America)
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Session: Improving asthma and anti-allergic therapy Session type: Thematic Poster Session Number: 2004
Disease area: Airway diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Anderson, E. Bleecker, H. Nelson, J. Corren, A. Emmett, D. Reilly, S. Yancey, H. Ortega (Research Triangle Park, NC, Winston Salem, NC, Denver, CO, Los Angeles, CA, United States Of America). Lack of effect of promoter, coding and 3‘ polymorphisms of the β2 -adrenergic receptor (ADRB2 ) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma. Eur Respir J 2008; 32: Suppl. 52, 2004
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Arg16Gly polymorphism of the β2 -adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthmaSource: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008
Effects of Arg16Gly polymorphism in ADRB2 gene on responses to salmeterol or montelukast added to inhaled corticosteroids in Japanese asthmatic subjects Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
The influence of polymorphisms of the β2 - adrenoceptor (AR) gene and the β2 -AR upstream peptide (BUP) on bronchoprotective tolerance development in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Differences in bronchoprotective subsensitivity between formoterol (FM) and salmeterol (SM) are associated with β2 -adrenoceptor polymorphism Source: Eur Respir J 2002; 20: Suppl. 38, 306s Year: 2002
Characterization of asthma exacerbations by Arg16Gly genotype in subjects with asthma receiving salmeterol alone or with fluticasone propionate Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Salmeterol response is not affected by beta2 -adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005
ADRB2R gene polymorphism (pol.) associated with the severity of cystic fibrosis(CF) and the effectiveness of the use of inhaled bronchodilator Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies Year: 2010
In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
ADRB2 Gly16Arg polymorphism, asthma control and lung function decline Source: Eur Respir J 2011; 38: 1029-1035 Year: 2011
E-cadherin (CDH-1 ) polymorphisms associate with airway remodeling, inflammation and FEV1 decline in asthma patients using inhaled corticosteroids (ICS) Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010
The effect of salmeterol/fluticasone propionate (SFC) on bronchial mucosal neutrophils and IL-8 gene expression in COPD Source: Eur Respir J 2007; 30: Suppl. 51, 354s Year: 2007
Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone Source: Eur Respir J 2003; 21: 123-128 Year: 2003
Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004
Effects of β2 agonists on mucociliary clearance (MCC) in patients with asthma - association to polymorphisms of the β2-adrenoceptor Source: Eur Respir J 2003; 22: Suppl. 45, 478s Year: 2003
Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Glucocorticosteroid receptor (GCR) gene isoforms expression in bronchial asthma (BA) patients Source: Annual Congress 2011 - Asthma: a heterogeneous disease Year: 2011